SOURCES SOUGHT
A -- Market Survey for National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Other Cardiovascular Conditions (GenTAC) - Renewal - Market Suvey - GenTAC Renewal
- Notice Date
- 8/10/2009
- Notice Type
- Sources Sought
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- NIH-NHLBI-SS-10-16
- Archive Date
- 9/8/2009
- Point of Contact
- Nora I Rivera, Phone: (301) 435-0712, Paul D McFarlane, Phone: 301-435-0345
- E-Mail Address
-
nr85c@nih.gov, pmcfarlane@mail.nih.gov
(nr85c@nih.gov, pmcfarlane@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Sources Sought Notice for GenTAC Renewal (Market Survey) SOURCES SOUGHT – MARKET RESEARCH NOTICE Notice Number:NIH-NHLBI-SS-10-16 Project Title:National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Other Cardiovascular Conditions (GenTAC) Background The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health is interested in renewing the Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions (GenTAC) contract for a Data Coordinating Center (DCC) to manage a registry of patients with conditions related to genetically-induced thoracic aortic aneurysms (TAAs). GenTAC has been established to facilitate studies by GenTAC investigators and others that will advance multiple scientific frontiers in thoracic aortic disease. Genetic, proteomic, clinical, and imaging data will be integrated systematically with outcomes data to determine the optimal clinical management of patients with genetically induced TAAs. To date, there are five Regional Clinical Centers (RCCs) (as subcontracts of the DCC) participating and over 1400 patients enrolled in the Registry. Although our understanding of the genetic basis of inherited predisposition to thoracic aortic disease has expanded, more than 80 percent of the genetic mutations responsible for genetically determined TAAs have yet to be identified. Further insight into the genes that trigger TAAs and aortic dissections and how to recognize individuals with these genetic mutations will help to prevent premature deaths due to thoracic aortic disease. Moreover, identification of a mutant gene that predisposes to TAA formation offers an opportunity to understand the pathologic mechanisms. Elucidation of the functional importance of genetic mutations has excellent potential for translation to therapeutic interventions, but is limited by difficulties in obtaining biospecimens for investigation and identification of kindred families by centers with expertise in genomic applications. Animal models of Marfan syndrome demonstrate functional significance of genetic mutations and suggest new strategies for therapeutic prevention and treatment. These findings require confirmation in patients. A central resource like GenTAC will serve as a conduit to address many of these questions. Purpose and Objectives The goal of the proposed program is to continue and expand data and biospecimens collection of patients with conditions related to genetically-induced TAAs. The overriding purpose of the Registry is to establish and analyze a central biospecimen and clinical data repository to better understand genetically triggered TAAs and their treatment. Ultimately the registry is an essential tool enabling new research to reduce cardiovascular complications which represent the primary cause of morbidity and premature death in persons with thoracic aortic disease and especially with genetically triggered TAAs. The Registry is the only avenue for these rare conditions to establish a resource that can be used by the research community to further understand and study the genetic basis of TAAs and to improve the diagnosis and clinical management of affected patients. (See attachment for more details)
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/NIH-NHLBI-SS-10-16/listing.html)
- Place of Performance
- Address: U.S.A., Rockville, Maryland, United States
- Record
- SN01906212-W 20090812/090811002259-4629295bac5b084fcf7fef986866406e (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |